Title: Identification of novel and available Bacillus anthracis inhibitors using drug repurposing approach and in-silico methods

Authors: Masood Aleeyar; Hamid Moghimi; Abbas Abbas Rouhollahi; Ramezan Ali Taheri

Addresses: Nanobiotechnolology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box 1435116471, Tehran, Iran ' Department of Microbial Biotechnology, School of Biology, College of Science, University of Tehran, P.O. Box: 6455-14155, Tehran, Iran ' Department of Microbial Biotechnology, School of Biology, College of Science, University of Tehran, P.O. Box: 6455-14155, Tehran, Iran ' Nanobiotechnolology Research Center, Baqiyatallah University of Medical Sciences, P.O. Box 1435116471, Tehran, Iran

Abstract: Anthrax is a dangerous disease all around the world and it can be lethal if it is not properly treated. In order to address this problem, we decided to use the combination of drug repurposing and structure-based drug discovery to identify useful and effective alternative treatment for the anthrax. In this study, we used molecular docking, molecular dynamics simulations and related analysis and found that Kanamycin, Tobramycin and Framycetin can be potential drugs for the treatment of anthrax. Moreover, because our identified compounds are FDA approved drugs, there is no need to pass any safety test and all of the hit compounds can be tested in real people.

Keywords: Bacillus anthracis; anthrax; microbiology; nucleotide hydrolase; structure-based drug discovery; virtual screening; docking; molecular dynamic; drug repurposing.

DOI: 10.1504/IJBRA.2021.120537

International Journal of Bioinformatics Research and Applications, 2021 Vol.17 No.6, pp.560 - 573

Accepted: 24 Feb 2020
Published online: 25 Jan 2022 *

Full-text access for editors Full-text access for subscribers Purchase this article Comment on this article